Testosterone May Help Treat MS in Men WebMD Mon, 14 May 2007 10:35 AM PDT Testosterone may help treat multiple sclerosis (MS) in men, according to a preliminary study.

Illinois Senate Votes Against Medical Marijuana Bill Join Together Online Mon, 14 May 2007 10:29 AM PDT The Illinois Senate, by a vote of 29-22, defeated attempts to allow doctors to prescribe medical marijuana to patients suffering from painful, debilitating diseases, such as cancer and multiple sclerosis, the St. Louis Post-Dispatch Springfield Bureau reported May 11.

Health and science news from UC campuses and labs UC Newswire Mon, 14 May 2007 9:44 AM PDT Glucosamine-like supplement inhibits multiple sclerosis, type-1 diabetes May 14, UCI -- A glucosamine-like dietary supplement has been found to suppress the damaging autoimmune response seen in multiple sclerosis and type-1 diabetes mellitus, according to University of California, Irvine health sciences researchers.

Groups Work With Researchers, Drug Cos. InteliHealth Mon, 14 May 2007 6:29 AM PDT HARTFORD, Conn. (AP) -- A major effort is under way in medical research circles to shave years off the time it takes for discoveries by scientists to be converted into treatments for patients.

Stem Cell Therapy International, Inc. Approved for OTC Bulletin Board and Commenced Trading on May 11, 2007 With Ticker ... SYS-CON Media Mon, 14 May 2007 10:35 AM PDT Stem Cell Therapy International, Inc. (OTCBB: SCII), a leading stem cell research company operating internationalaffiliate treatment clinics, announced today that its common stock has beenapproved for quotation on the National Association of Security Dealers(NASD) OTC Bulletin Board (OTCBB) commencing on May 11, 2007. The Company'sticker symbol is 'SCII' and the Company's web site is ...

Biogen Idec And Vernalis Plc Announce The Start Of Phase II Program Of BIIB014 In Parkinson's Disease Medical News Today Mon, 14 May 2007 0:04 AM PDT Biogen Idec (NASDAQ: BIIB) and Vernalis plc (LSE: VER, Nasdaq: VNLS) today announced the initiation of the Phase II program of BIIB014 (also known as V2006), an oral compound, for the treatment of Parkinson's disease. BIIB014 is an adenosine A2A receptor antagonist that may offer a non-dopaminergic therapy for patients with Parkinson's disease. [click link for full article]

New Therapeutic Targets For Neurodegenerative Diseases
Medical News Today Sun, 13 May 2007 6:04 PM PDT
The focus of work in the Neurosciences Department's Neurobiology Laboratory at the University of the Basque Country's Faculty of Medicine and Odontology is the investigation of the molecular and cellular bases of neurodegenerative illnesses - those that affect the brain and the spinal cord. [click link for full article]